BioSpace News Archive

The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community

Centinel Spine®, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that it has successfully surpassed the initial 1000 implantations with its newest implant system technology platform: FLX™ 3D-Printed Porous-Titanium Interbody Devices.

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) from March 2, 2017, through February 22, 2019 (the “Class Period”).

Cipla USA Inc. (“Cipla USA”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”), announced the acquisition of the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. (“Achaogen”) in a Chapter 11, U.S. Bankruptcy Code auction of Achaogen’s assets

Prodigo Solutions teamed up with Amazon Business to automate B2B eCommerce transactions with trading partners through EDI and other electronic protocols.

Alfa Chemistry, a leading chemical company located in New York, announced the launch of a wide range of featured biomaterial products for expanding their production lines to meet the increasing demands from their customers.

ASPCA fleet of mobile and stationary spay/neuter clinics provides high-quality, low-cost surgery to tens of thousands of pet owners and rescue groups each year

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that two-year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011,

Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 8, 2019 following release of its second quarter 2019 financial results.

Torchmark Corporation (NYSE: TMK) reported today that for the quarter ended June 30, 2019, net income was $1.67 per diluted common share, compared with $1.59 per diluted common share for the year-ago quarter.